ArticleBMC genomics2016
microRNA analysis of gastric cancer patients from Saudi Arabian population.
Article in BMC genomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- MiR-3613-5p targets AQP4 to promote the progression of chronic atrophic gastritis to gastric cancer.Frontiers in pharmacology · 2025Article
- Potential Regulation ofInternational journal of molecular sciences · 2025Article
- Long noncoding RNA KCNMA1-AS2 regulates the function of colorectal cancer cells and sponges miR-1227-5p.BMC cancer · 2024Article
- Ago2/CAV1 interaction potentiates metastasis via controlling Ago2 localization and miRNA action.EMBO reports · 2024Article
- Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p.Scientific reports · 2024Article
- Circ_BBS9 as an early diagnostic biomarker for lung adenocarcinoma: direct interaction with IFIT3 in the modulation of tumor immune microenvironment.Frontiers in immunology · 2024Article
- Exosome and lipid metabolism-related genes in pancreatic adenocarcinoma: a prognosis analysis.Aging · 2023Article
- Influence of Clinical Factors on miR-3613-3p Expression in Colorectal Cancer.International journal of molecular sciences · 2023Article
- The Effect of miR-4800 Restoration on Proliferation and Migration of Human Breast Cancer CellsAdvanced pharmaceutical bulletin · 2023Article
- Bioinformatics and Expression Analyses of miR-639, miR-641, miR-1915-3p and miR-3613-3p in Colorectal Cancer Pathogenesis.Journal of Cancer · 2023Article
- Identifying pancreatic cancer-associated miRNAs using weighted gene co-expression network analysis.Oncology letters · 2022Article
- A Signature of Three microRNAs Is a Potential Diagnostic Biomarker for GlioblastomaIranian biomedical journal · 2022Article
- Atrophic gastritis and gastric cancer tissue miRNome analysis reveals hsa-miR-129-1 and hsa-miR-196a as potential early diagnostic biomarkers.World journal of gastroenterology · 2022Article
- Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Review
- Hsa_circRNA_0040462: a sensor of cells' response to CAP treatment with double-edged roles on breast cancer malignancy.International journal of medical sciences · 2022Article
- Identification of gene signatures and potential therapeutic targets for acquired chemotherapy resistance in gastric cancer patients.Journal of gastrointestinal oncology · 2021Article
- MicroRNA-3613-3p functions as a tumor suppressor and represents a novel therapeutic target in breast cancer.Breast cancer research : BCR · 2021Article
- Suppressor of Ty 16 promotes lung cancer malignancy and is negatively regulated by miR-1227-5p.Cancer science · 2020Article
- Screening potential microRNAs associated with pancreatic cancer: Data mining based on RNA sequencing and microarrays.Experimental and therapeutic medicine · 2020Article
- Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of small non-coding microRNAs (miRNAs) in several types of cancer has been evident. However, its expression studies have never been performed in gastric cancer (GC) patients from Saudi population. First time this study was conducted to identify miRNAs that are differentially expressed in GC patients compared with normal controls.
methodsWe investigated the role of miRNAs in GC patients using formalin-fixed paraffin-embedded (FFPE) tissues of 34 samples from GC patients (early stage = 7 and late-stage = 26) and 15 from normal control. We have used miRNA microarray analysis and validated the results by Real-time quantitative PCR (RT-qPCR).
resultsWe obtained data of 1082 expressed genes, from cancer tissues and noncancerous tissues (49 samples in total). Where 129 genes were up-regulated (P > 0.05) and 953 genes (P > 0.05) were down-regulated in 49 FFPE tissue samples. Only 33 miRNAs had significant expression in early and late-stage cancer tissues. After candidate miRNAs were selected, RT-qPCR further confirmed that four miRNAs (hsa-miR-200c-3p, hsa-miR-3613, hsa-miR-27b-3p, hsa-miR-4668-5p) were significantly aberrant in GC tissues compared to the normal gastric tissues.
conclusionsIn this study we provide miRNAs profile of GC where many miRNAs showed aberrant expression from normal tissues, suggesting their involvement in the development and progression of gastric cancer. In early and late-stage miR-200c-3p showed significant down regulation as compare to control samples. Many of miRNAs reported in our study showing up-regulation are new and not reported before may be due to population difference. In conclusion, our results suggest that miR-200c-3p had potential to use as diagnostic biomarker for distinguishing GC patients from normal individuals and can be used for diagnosis of cancer at early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.